Top 10 Stocks To Own For 2018


Stocks fell for a second consecutive day but still remain within one good day of an all-time high.

Getty Images

The S&P 500 dropped 0.3% to 2,368.38 today, while the Dow Jones Industrial Average dipped 29.58 points, or 0.1%, to 20,924.76. The Nasdaq Composite fell 0.3% to 5,833.93. The S&P 500 is still just 1.4% off its all-time high.

Earlier today I looked at some of the reasons the market could be set for a fall. But that doesn’t have to be the case, despite the S&P 500′s 5.7% rally this year. The folks at Bespoke Investment Group note that the S&P 500 is the least overbought it’s been in a month:


After reaching levels well into extreme overbought territory in the last few weeks, the S&P 500 has been working its way down to less overbought levels as the market trades sideways and its moving averages and trading ranges play catch up. As of mid-day today, the S&P 500 is still trading at short-term overbought levels, but the degree to which it is overbought is the lowest in a month. While this doesnt suggest that the market is trading at attractive levels from a timing perspective, it illustrates a fact that we have cited numerous times in the past and that is that just because a market is overbought doesnt necessarily mean that it has to sell-off in order to work off the overbought condition. Corrections can occur in both price and time.

Top 10 Stocks To Own For 2018: MicroStrategy Incorporated(MSTR)


Advisors’ Opinion:

  • [By Chris Neiger]

    MicroStrategy (NASDAQ:MSTR) reported its first-quarter results on April 27, and the company saw its total revenue tick up by 1.3% year over year. Just as with the company’s fourth-quarter results, MicroStrategy’s management said foreign-currency headwinds continued to have a negative impact on the company’s overall sales.

Top 10 Stocks To Own For 2018: L-3 Communications Holdings, Inc.(LLL)


Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows ViaSat, Inc plus mid to large cap communications stockslikeHarris Corporation (NYSE: HRS) and L-3 Communications Holdings, Inc (NYSE: LLL)had been moving in tandem until last yearwhile small cap Gogo Inc has underperformed:

  • [By Paul Ausick]

    Five teams are expected to compete for the contract: Boeing Co. (NYSE: BA) has joined with Saab to offer a clean-sheet design; Northrop Grumman Corp. (NYSE: NOC) has teamed up with BAE Systems and L-3 Communications Holdings Inc. (NYSE: LLL) on another clean-sheet design; Lockheed Martin Corp. (NYSE: LMT) and Korea Aerospace Industries (KAI) are going with a modified KAI T-50; Raytheon Corp. (NYSE: RTN) has joined with Italy’s Leonardo and Canada’s CAE Inc. (NYSE: CAE) on a version of Leonardo’s M-346 trainer that it calls the T-100; and privately held Sierra Nevada has partnered with Turkish Aerospace Industries (TAI) on another clean-sheet design.

Top 10 Stocks To Own For 2018: SemiLEDS Corporation(LEDS)


Advisors’ Opinion:

  • [By Lisa Levin]

    SemiLEDs Corporation (NASDAQ: LEDS) was down, falling around 17 percent to $6.75 following Q2 earnings report. SemiLEDS reported a Q3 loss of $1.06 per share on revenue of $2.4 million.

  • [By Monica Gerson]

    SemiLEDs Corporation (NASDAQ: LEDS) is estimated to post its quarterly earnings.

    Staffing 360 Solutions Inc (NASDAQ: STAF) is expected to post a quarterly loss at $0.28 per share.

Top 10 Stocks To Own For 2018: tronc, Inc. (TRNC)


Advisors’ Opinion:

  • [By Lee Jackson]

    Tronc Inc. (NASDAQ: TRNC) had a gigantic buyer recently. Michael Ferro, who is a director, purchased a stunning 2,500,000 sharesat $15 apiece. The total for the trade was an incredible $37,500,000.Thismultiplatform media and marketing solutions company publishes newspapers in the United States, as well as provides a suite of digital marketing services for local, regional and national marketers. Its shares ended trading on Friday at $13.87.Their 52-week trading range is $8.76 to $17.93, and the Wall Street consensus price target is $21.

Top 10 Stocks To Own For 2018: Texas Roadhouse, Inc.(TXRH)


Advisors’ Opinion:

  • [By Jon C. Ogg]

    Texas Roadhouse Inc. (NASDAQ: TXRH) was raised to Buy from Neutral at BTIG Research.

    USG Corp. (NYSE: USG) was reiterated as Hold but the price target was raised to $35 from $29 (versus a $34.23 close) at Jefferies.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Texas Roadhouse (NASDAQ:TXRH) and Garmin (NASDAQ:GRMN)made large moves following their quarterly earnings announcements.

  • [By Dan Caplinger]

    Steakhouse chain Texas Roadhouse (NASDAQ:TXRH) has had to deal with an extremely difficult business environment for restaurant companies, and investors know all too well how tough times can hurt major players in the industry. Last quarter, Texas Roadhouse disappointed investors with sluggish results, and the company wanted to start 2017 on a better footing.

  • [By Teresa Rivas]

    Texas Roadhouse(TXRH) tumbled more than 12% on Wednesday as itsfourth-quarter earningsand revenue fell short of expectations.


    Pixabay

    The restaurant chain said it earned 29 cents a share on revenue of $484.7 million. Analysts were expecting earnings per share of 38 cents on revenue of $497.3 million.

    Same-restaurant sales grew 1.2% at company restaurants and 2% at domestic franchises. For the first 55 days of the first quarter, Texas Roadhouse said that same-store sales rose 1.5%.

    The company also raised its dividend 10.5% to 21 cents a share.

    Some analysts urged investors to keep the faith in the stock.Barclay’s JeffreyBernsteinreiterated an Overweight rating and $47 price target on thestock:


    We believe TXRH fundamentals remain best-in-class. That said, the near-term focus remains on directional comps. And not unlike the broader industry, TXRH comps eased significantly to close 2016. Such led to disappointing 4Q16 results from top to bottom. Importantly, while the brand ‘is not immune’ to industry comp headwinds, the relative outperformance to the category was maintained. Looking to 2017, key guidance metrics were reiterated. While questions remain on whether the recent easing of industry comps will persist, we remain comforted by TXRH’s relative outperformance and easing comps as we move through 2017.


    Maxim’s Stephen Andersonreiterated a Buy rating, although he took his price target down $4, to $52:

    In our view, TXRH is not immune to the broader slowdown in Casual Dining, but we believe the company will emerge stronger than peers in the next few quarters.TXRHs disappointing 4Q16 comp of +1.3% (blended) was pulled down by a rare negative comp month in December (-2.1%), marking the first time this occurred in almost four years. Comps were +3% or better in both October and November, and comps so far in 1Q17 are positive despite a stormy start to the quarter in

  • [By Joe Tenebruso]

    Fortunately, well-chosen dividend-growth stocks can help you accomplish both of these goals. And with its powerful wealth-building combination of increasing dividend payouts and share-price appreciation, Texas Roadhouse (NASDAQ:TXRH)is one of the best available in the market today.

Top 10 Stocks To Own For 2018: Codexis, Inc.(CDXS)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    While companies with lower-priced shares are often riskier than those with higher prices, some companies trading under $5 per share have intriguing potential. Investors searching for overlooked growth opportunities should consider industrial biotech BioAmber (NYSE:BIOA), pharmaceutical services company Codexis (NASDAQ:CDXS), and one-trick-pony biopharma Keryx Biopharmaceuticals (NASDAQ:KERX).

  • [By Jim Robertson]

    On Tuesday, our Under the Radar Moversnewsletter suggested taking a long/bullish position in small cap biocatalysts developer Codexis, Inc (NASDAQ: CDXS):

Top 10 Stocks To Own For 2018: Coherus BioSciences, Inc.(CHRS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter. Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba. Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision. Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results. Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter. AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday. Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share. Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday. Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday. Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Ben Levisohn]

    Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:

    Agence France-Presse/Getty Images

    The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…


    Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.

    Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.

Top 10 Stocks To Own For 2018: The Herzfeld Caribbean Basin Fund, Inc.(CUBA)


Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    This "Trump pick" is a snub to the President’s trade and diplomatic reversals of Obama’s wins regarding Cuba. We are buying back Herzfeld Caribbean Basin Fund (CUBA), following in the footsteps of its founder, Tom Herzfeld, and his son Erik.

Top 10 Stocks To Own For 2018: OncoMed Pharmaceuticals, Inc.(OMED)

Advisors’ Opinion:

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.

  • [By Paul Ausick]

    OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.

  • [By Teresa Rivas]

    OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.

    Pixabay

    That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.

    Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.


    More detail from the note:

    This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cas h to run operations through 3Q18.

    OncoMed is down 36.1% to $5.60 this afternoon.

Top 10 Stocks To Own For 2018: Acacia Communications, Inc. (ACIA)

Advisors’ Opinion:

  • [By Scott Rubin]

    Shares of Acacia Communications, Inc. (NASDAQ: ACIA) soared on the back of the company's second-quarter earnings results, closing the session up 41 percent to $95.67. Planet Fitness Inc (NYSE: PLNT) added 10 percent after reporting better-than expected results. The stock closed at $22.36. Steel stocks fell during Friday's session. United States Steel Corporation (NYSE: X) lost 7 percent to $21.06 and AK Steel Holding Corporation (NYSE: AKS) fell 6 percent to $5.03.

  • [By Lisa Levin]

    Acacia Communications, Inc. (NASDAQ: ACIA) was down, falling around 14 percent to $54.34 after the company issued a weak forecast for the current quarter. However, the company’s Q4 results exceeded expectations.

  • [By Evan Niu, CFA]

    Shares of optical component companies have dropped today, includingOclaro (NASDAQ:OCLR), Acacia (NASDAQ:ACIA), Lumentum (NASDAQ:LITE), and Finisar (NASDAQ:FNSR), whose shares were down 11%, 11%, 6%, and 3%, respectively, as of 3:30 p.m. EDT, after the U.S. broadened its investigation regarding compliance with sanctions programs.

Leave a Reply

Your email address will not be published. Required fields are marked *